Arbovirus infection study in the Indian Ocean
Treatments studied
Part of Infections clinical trials.
This study looks at patients with suspected, probable, or confirmed arbovirus infections (like dengue, chikungunya, or Zika) to understand what factors lead to hospitalization and how severe the illness can be. It may include adults, children, and even newborns if they might have been exposed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Weigh more than 2.5 kilograms (about 5.5 pounds) on the day you join
- Be seen in a participating hospital department (emergency room, inpatient, day hospital, or clinic)
- Have a suspected, probable, or confirmed arbovirus infection (for example, dengue, chikungunya, or Zika)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment (PC-CHIK-V) for newborns whose mothers had chikungunya around the time of birth. The goal is to see if the treatment can prevent or reduce the infection in babies. Babies who are not treated will also be followed for comparison.
This study is looking at how viruses like those spread by mosquitoes (arboviruses) affect people in Fiji. If you join, researchers will track your health over time to find better ways to prevent and treat these infections.
This trial uses a blood test to look at how your immune system fights certain viruses spread by insects (like mosquitoes). Your participation could help doctors better understand and diagnose these infections.
This study looks at how infections spread in villages in Cambodia. If you live in a participating village, you might help us understand and prevent disease outbreaks.
This trial tests different experimental drugs to treat dengue early. It aims to find which treatment works best and is safe for patients who start within 48 hours of fever.
This trial tests how the dengue virus affects healthy adults who have never been exposed to dengue or similar viruses. You would be given a controlled dose of the virus and closely monitored to help researchers understand the infection and develop better treatments or vaccines.
Hear when a new Arbovirus Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.